BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-110@catalystbrief.girapphe.com
DTSTAMP:20261117T181547Z
LAST-MODIFIED:20261117T181547Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: Hoffmann-La Roche — Atezolizumab [Nov 2026]
DESCRIPTION:Phase 3 primary completion: A Study in Participants Previously 
 Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezoli
 zumab Study (IMbrella A).\nSource: https://clinicaltrials.gov/study/NCT031
 48418\nhttps://catalystbrief.girapphe.com/e/110?lang=en\nNot investment ad
 vice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/110?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
